Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the improvement in signs of photoaging and subject
satisfaction after combination, global facial and/or neck treatment with IncobotulinumA
(Xeomin), HA (Belotero) and/or calcium hydroxyapatite (Radiesse+, Radiesse Classic). All
products will be used on-label FDA-cleared indications.